Several options are available for the treatment of breast cancer, including local therapies such as surgery and radiation therapy, as well as systemic therapies such as chemotherapy, hormone therapy, targeted therapy, and immunotherapy. While...
The pandemic may make cancer clinical trials more patient-centric, and more news of the week from Cancer Today.
A study indicates that some breast cancer patients who receive mastectomy and reconstruction may be at risk of persistent drug use following surgery.
Study finds adherence to follow-up screening guidelines is low among people at high risk of developing lung cancer, and more news of the week from Cancer Today.
Study suggests that germline genetics may influence lung cancer risk in this patient population. Native American ancestry was associated with increased mutations in the EGFR gene in lung cancer patients from Latin American countries,...
Roughly 6 percent of men and women in the United States will be diagnosed with lung and bronchus cancer during their lifetime. While both the incidence and mortality rates have been steadily decreasing in...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a grim prognosis. While early-stage PDAC may be removed by surgery, PDACs that have spread beyond the pancreas are generally deemed inoperable. Unfortunately, 80 to...
The FDA approved the use of an immunotherapeutic in combination with chemotherapy to treat certain patients with triple-negative breast cancer.
Steroid used to prevent swelling in the brains of patients with glioblastoma may have “detrimental effect” on treatment with immune checkpoint inhibitors.
The FDA granted approval to expand the use of a minimally invasive biomarker test to identify certain patients with ovarian, lung, breast, or prostate cancer eligible for treatment with specific molecularly targeted therapeutics.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More